aflibercept (Eylea)

Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Aflibercept helps in ME patients with DR after cataract surgeryPatients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population.
Anti-angiogenic agent, platform planned for human trialFindings from preclinical studies show that a novel intravitreal depot of an anti-angiogenic drug releases the medication over a period of at least 6 months, is well-tolerated, and prevents VEGF-induced retinal vascular leakage.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
ARVO 2016 meeting paves path for personalized medicineEmerging trends and hot topics in eye and vision research filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.
FDA grants priority review to aflibercept for diabetic retinopathy in patients with DMEThe FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
Primary care optometry: addressing the posterior segmentDuring the American Academy of Optometry's Academy 2014, experts elucidated with promising directions for retinal and other posterior eye problems.
AMD patients respond to aflibercept treatmentA study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
STAAR Surgical, Regeneron expanding products to JapanSTAAR Surgical and Regeneron Pharmaceuticals—in collaboration with Bayer Healthcare—are making strides in Japan.